newsEvidence level DIndependent

Evidence page

FDA Approves First Angiogenesis Inhibitor To Treat Colorectal Cancer

ScienceDaily (reprinting U.S. Food and Drug Administration release)

Published Feb 27, 2004accessed Nov 11, 2026Updated Nov 11, 2026

Original source

https://www.sciencedaily.com/releases/2004/02/040227071334.htm

sciencedaily.com

Verification

Verification	Independent of the subject
Evidence level	D · Journalism / industry
Independent	Independent of the subject
Source	news
Link status	Reachable at last check

Official claims are statements by the provider; they are not verified by worldwiki unless marked otherwise. Source policy

Cited by (1)

FactAngiogenesis: First US-approved angiogenesis inhibitor = Bevacizumab (Avastin), an anti-VEGF monoclonal antibody, approved by the FDA for first-line treatment of metastatic colorectal cancer